Real-time gastric juice analysis with EndoFaster for H. pylori diagnosis: a large, multicentre study.
Journal
European journal of gastroenterology & hepatology
ISSN: 1473-5687
Titre abrégé: Eur J Gastroenterol Hepatol
Pays: England
ID NLM: 9000874
Informations de publication
Date de publication:
01 11 2022
01 11 2022
Historique:
aheadofprint:
12
09
2022
entrez:
28
9
2022
pubmed:
29
9
2022
medline:
1
10
2022
Statut:
ppublish
Résumé
Helicobacter pylori infection is the main cause of the most frequent gastroduodenal diseases. Because its prevalence is decreasing in developed countries, gastric biopsies are negative in several patients. By measuring ammonium in the gastric juice, EndoFaster allows to exclude H. pylori infection during endoscopy. This study aimed to assess the accuracy of device versions working with either 6 ml or 3 ml of gastric juice. This prospective study involved 12 endoscopic units. During endoscopy, EndoFaster testing was performed and standard five gastric biopsies were taken. The accuracy was calculated by considering histological assessment as the gold standard for H. pylori diagnosis. Gastric juice analysis was attempted in 1279 patients, but it failed in 131 (15.5%) and in 10 (2.3%), with the 6 ml and the 3 ml device, respectively (P < 0.001). Overall, EndoFaster detected H. pylori infection with an 86.3% sensitivity, 83.3% specificity, 52.7% positive predictive value, 96.6% negative predictive value and 83.8% accuracy. The performance was not affected either by ongoing proton pump inhibitor therapy or a previous H. pylori eradication. No significant difference in accuracy emerged between the two versions of the device. The novel version of the EndoFaster device operating with 3 ml gastric juice may be performed in virtually all patients, and it allows excluding H. pylori infection with a very high accuracy. Gastric biopsies can be avoided in a definite portion of cases without endoscopic lesions or other clinical indications.
Sections du résumé
BACKGROUND
Helicobacter pylori infection is the main cause of the most frequent gastroduodenal diseases. Because its prevalence is decreasing in developed countries, gastric biopsies are negative in several patients. By measuring ammonium in the gastric juice, EndoFaster allows to exclude H. pylori infection during endoscopy. This study aimed to assess the accuracy of device versions working with either 6 ml or 3 ml of gastric juice.
STUDY DESIGN
This prospective study involved 12 endoscopic units. During endoscopy, EndoFaster testing was performed and standard five gastric biopsies were taken. The accuracy was calculated by considering histological assessment as the gold standard for H. pylori diagnosis.
RESULTS
Gastric juice analysis was attempted in 1279 patients, but it failed in 131 (15.5%) and in 10 (2.3%), with the 6 ml and the 3 ml device, respectively (P < 0.001). Overall, EndoFaster detected H. pylori infection with an 86.3% sensitivity, 83.3% specificity, 52.7% positive predictive value, 96.6% negative predictive value and 83.8% accuracy. The performance was not affected either by ongoing proton pump inhibitor therapy or a previous H. pylori eradication. No significant difference in accuracy emerged between the two versions of the device.
CONCLUSION
The novel version of the EndoFaster device operating with 3 ml gastric juice may be performed in virtually all patients, and it allows excluding H. pylori infection with a very high accuracy. Gastric biopsies can be avoided in a definite portion of cases without endoscopic lesions or other clinical indications.
Identifiants
pubmed: 36170680
doi: 10.1097/MEG.0000000000002429
pii: 00042737-202211000-00004
doi:
Substances chimiques
Ammonium Compounds
0
Proton Pump Inhibitors
0
Types de publication
Journal Article
Multicenter Study
Langues
eng
Sous-ensembles de citation
IM
Pagination
1121-1124Informations de copyright
Copyright © 2022 Wolters Kluwer Health, Inc. All rights reserved.
Références
Alakkari A, Zullo A, O’Connor HJ. Helicobacter pylori and nonmalignant diseases. Helicobacter 2011; 16 Suppl 1:33–37.
Rokkas T, Rokka A, Portincasa P. A systematic review and meta-analysis of the role of Helicobacter pylori eradication in preventing gastric cancer. Ann Gastroenterol 2017; 30:414–423.
Zullo A, Rago A, Felici S, Licci S, Ridola L, Caravita di Toritto T. Onset and progression of precancerous lesions on gastric mucosa of patients treated for gastric lymphoma. J Gastrointestin Liver Dis 2020; 29:27–31.
Gravina AG, Zagari RM, De Musis C, Romano L, Loguercio C, Romano M. Helicobacter pylori and extragastric diseases: a review. World J Gastroenterol 2018; 24:3204–3221.
Sonnenberg A. Epidemiology of Helicobacter pylori. Aliment Pharmacol Ther 2022; 55 Suppl 1:S1–S13.
Lahner E, Zullo A, Hassan C, Perri F, Dinis-Ribeiro M, Esposito G, et al.; MAG-Study Group. Detection of gastric precancerous conditions in daily clinical practice: a nationwide survey. Helicobacter 2014; 19:417–424.
Zullo A, Germanà B, Galliani E, Iori A, de Pretis G, Manfredi G, et al. Optimizing the searching for H. pylori in clinical practice with EndoFaster. Dig Liver Dis 2021; 53:772–775.
Sonnenberg A, Lash RH, Genta RM. A national study of Helicobactor pylori infection in gastric biopsy specimens. Gastroenterology 2010; 139:1894–1901.e2; quiz e12.
Zullo A, Fiorini G, Bassotti G, Bachetti F, Monica F, Macor D, et al. Upper endoscopy in patients with extra-oesophageal reflux symptoms: a multicentre study. GE Port J Gastroenterol 2020; 27:312–317.
Costamagna G, Zullo A, Bizzotto A, Spada C, Hassan C, Riccioni ME, et al. Real-time diagnosis of H. pylori infection during endoscopy: accuracy of an innovative tool (EndoFaster). United European Gastroenterol J 2016; 4:339–342.
Carretero-Barrio I, Rodajo-Fernandez T, Romio E, Sanchez-Rodriguez E, Vázquez-Sequeiros E, et al. Comparison between real-time ammonium and pH measurement, immunohistochemistry, and histochemistry for the diagnosis of Helicobacter pylori . J Clin Gastroenterol 2021; 56:e263–e267.
Zullo A, Germanà B, Galliani E, Iori A, De Pretis G, Manfredi G, et al. Real-time EndoFaster improves Helicobacter pylori detection in chronic active gastritis. J Clin Pathol 2021.
Dixon MF, Genta RM, Yardley JH, Correa P. Classification and grading of gastritis. The updated Sydney System. International Workshop on the Histopathology of Gastritis, Houston 1994. Am J Surg Pathol 1996; 20:1161–1181.
Malfertheiner P, Megraud F, O’Morain CA, Gisbert JP, Kuipers EJ, Axon AT, et al.; European Helicobacter and Microbiota Study Group and Consensus panel. Management of Helicobacter pylori infection-the Maastricht V/Florence Consensus Report. Gut 2017;66:6–30.
Yuan C, Adeloye D, Luk TT, Huang L, He Y, Xu Y, et al.; Global Health Epidemiology Research Group. The global prevalence of and factors associated with Helicobacter pylori infection in children: a systematic review and meta-analysis. Lancet Child Adolesc Health 2022; 6:185–194.
Italian Ministry of Health - ALTEMS. HTA ENDOFASTER: strumento automatico di endoscopia chimica. https://altems.unicatt.it/altems-Mini_HTA_Strumento_Automatico_di_endoscopia_chimica.pdf .
Siavoshi F, Saniee P, Khalili-Samani S, Hosseini F, Malakutikhah F, Mamivand M, et al. Evaluation of methods for H. pylori detection in PPI consumption using culture, rapid urease test and smear examination. Ann Transl Med 2015; 3:11.
Zullo A, Manta R, De Francesco V, Fiorini G, Hassan C, Vaira D. Diagnostic yield of upper endoscopy according to appropriateness: a systematic review. Dig Liver Dis 2019; 51:335–339.
Correa P. Human gastric carcinogenesis: a multistep and multifactorial process–First American Cancer Society Award Lecture on Cancer Epidemiology and Prevention. Cancer Res 1992; 52:6735–6740.
Genta RM, Lash RH. Helicobacter pylori-negative gastritis: seek, yet ye shall not always find. Am J Surg Pathol 2010; 34:e25–e34.
Genta RM, Sonnenberg A. Helicobacter-negative gastritis: a distinct entity unrelated to Helicobacter pylori infection. Aliment Pharmacol Ther 2015; 41:218–226.
Glickman JN, Noffsinger A, Nevin DT, Ray M, Lash RH, Genta RM. Helicobacter infections with rare bacteria or minimal gastritis: expecting the unexpected. Dig Liver Dis 2015; 47:549–555.
Pimentel-Nunes P, Libânio D, Marcos-Pinto R, Areia M, Leja M, Esposito G, et al. Management of epithelial precancerous conditions and lesions in the stomach (MAPS II): European Society of Gastrointestinal Endoscopy (ESGE), European Helicobacter and Microbiota Study Group (EHMSG), European Society of Pathology (ESP), and Sociedade Portuguesa de Endoscopia Digestiva (SPED) guideline update 2019. Endoscopy 2019; 51:365–388.
Tucci A, Bisceglia M, Rugge M, Tucci P, Marchegiani A, Papadopoli G, et al. Clinical usefulness of gastric-juice analysis in 2007: the stone that the builders rejected has become the cornerstone. Gastrointest Endosc 2007; 66:881–890.
Cazzato M, Esposito G, Galli G, Pilozzi E, Lahner E, Corleto VD, et al. Diagnostic Accuracy of EndoFaster® and narrow-band imaging endoscopy in patients with impaired gastric acid secretion: a real-time prospective study. Gastroenterol Res Pract 2021; 2021:6616334.